HomeTrialNCT06646289
🔬NCT06646289Phase 2ACTIVE NOT RECRUITING

A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP)

Study Summary

The purpose of this study is to assess the safety and tolerability of subretinal delivery of Adeno-associated Virus Vector (AAV5 hRKp.RPGR) gene therapy in adults and children with X-linked retinitis pigmentosa.

View on ClinicalTrials.gov ↗
Study Details
Enrollment24 participants
Primary Completion
Lead SponsorJanssen Research & Development, LLC
Data Retrieved2026-04-11 02:55:31.550490+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.